Charalabos-Markos Dintsios

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

Matthias Herpers, Charalabos-Markos Dintsios, C. Dintsios, 2019, The European Journal of Health Economics.

PCV80 TISSUE ENGINEERING OF VALVEDVENOUS CONDUITS (VVC) VERSUS CONSERVATIVE THERAPY IN PATIENTS WITH CHRONICVENOUS INSUFFICIENCY (CVI). A DECISION ANALYTIC MODEL USING EXPERT ESTIMATED UTILITIES BASED ON DERIVED DATA FROM ANIMAL STUDIES AS A PRE-MARKETINGTECHNOLOGY ASSESSMENT APPROACH WITH GERMAN DA

Christian Krauth, Ansgar Gerhardus, Charalabos-Markos Dintsios, 2008 .

Proposed Methods of the IQWiG for Cost-Benefit-Assessment of Medical Interventions

Charalabos-Markos Dintsios, Klaus Koch, Peter T. Sawicki, 2009 .

Using the analytic hierarchy process to elicit patient preferences: prioritizing multiple outcome measures of antidepressant drug treatment.

Maarten J. IJzerman, Maarten J Ijzerman, Fabian Volz, 2012, The patient.

Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences

Maarten J. IJzerman, Maarten J Ijzerman, Fabian Volz, 2011, International Journal of Technology Assessment in Health Care.

Reflections on the Changing Face of German Pharmaceutical Policy

Charalabos-Markos Dintsios, Stephanie Stock, S. Stock, 2011, PharmacoEconomics.

Using the Analytic Hierarchy Process to Elicit Patient Preferences

Maarten Joost IJzerman, Maarten J. IJzerman, Marjan J.M. Hummel, 2012, The Patient: Patient-Centered Outcomes Research.

Information on ethical issues in health technology assessment: How and where to find them

Charalabos-Markos Dintsios, C. Dintsios, A. Gerber, 2010, International Journal of Technology Assessment in Health Care.